TY - JOUR
T1 - Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients
AU - Patel, Divya A.
AU - Unger, Elizabeth R.
AU - Walline, Heather
AU - Opipari, Anthony W.
AU - Lee, Daisy R.
AU - Flowers, Lisa C.
AU - Ruffin, Mack T.
N1 - Funding Information:
The authors thank Jay Stoerker (Sequenom Center for Molecular Medicine, Ann Arbor, MI) for technical assistance and interpretation of the findings. We gratefully acknowledge the women who participated in this research. Funding : This work was supported by National Cancer Institute (NCI) grants K07 CA120040 (Patel) and K24 CA080846 (Ruffin), and also by NCI's Early Detection Research Network through IAA Y1-CN-5005-01 and Y1-CN-0101-01 . The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies. Ethical approval : This study protocol was deemed “not regulated” by the Institutional Review Board of the University of Michigan Medical School as the data could not be linked directly or indirectly to a specific individual.
PY - 2011/4
Y1 - 2011/4
N2 - Background: Persistent infection with high-risk human papillomavirus (HPV) types is necessary for the development of high-grade cervical dysplasia and cervical carcinoma. The presence of HPV DNA in the blood of cervical cancer patients has been reported; however, whether HPV DNA is detectable in the blood of patients with pre-invasive cervical disease is unclear. Objectives: The objectives of this study were to determine if HPV 16 and HPV 18 DNA could be detected in the serum of colposcopy clinic patients, and if serum HPV detection was associated with grade of cervical disease and HPV cofactors. Study design: Samples were selected from a biorepository collected from non-pregnant, HIV-negative women ages 18-69 attending colposcopy clinics at two urban public hospitals. Cervical disease status was based on review of colposcopy, biopsy and cytology findings. Serum HPV DNA detection was conducted using a novel PCR and mass spectroscopy-based assay. Results: Of the 116 adequate serum samples, all (100%) were negative for HPV 16 and HPV 18. Over half (51.7%) of participants had cervical HPV 16 and/or HPV 18 infection. Nearly one-third (31.1%) had high grade, 10.3% had low grade, and 50.9% had no cervical disease. Nearly one-third (28.5%) had ever regularly smoked cigarettes, 70.7% had early onset of sexual intercourse, and 75% had ever used oral contraceptives. Conclusions: In this colposcopy clinic population with a range of clinical characteristics and established HPV cofactors, HPV DNA was undetectable in their serum. Our findings suggest that serum HPV DNA detection is not a cervical cancer screening tool.
AB - Background: Persistent infection with high-risk human papillomavirus (HPV) types is necessary for the development of high-grade cervical dysplasia and cervical carcinoma. The presence of HPV DNA in the blood of cervical cancer patients has been reported; however, whether HPV DNA is detectable in the blood of patients with pre-invasive cervical disease is unclear. Objectives: The objectives of this study were to determine if HPV 16 and HPV 18 DNA could be detected in the serum of colposcopy clinic patients, and if serum HPV detection was associated with grade of cervical disease and HPV cofactors. Study design: Samples were selected from a biorepository collected from non-pregnant, HIV-negative women ages 18-69 attending colposcopy clinics at two urban public hospitals. Cervical disease status was based on review of colposcopy, biopsy and cytology findings. Serum HPV DNA detection was conducted using a novel PCR and mass spectroscopy-based assay. Results: Of the 116 adequate serum samples, all (100%) were negative for HPV 16 and HPV 18. Over half (51.7%) of participants had cervical HPV 16 and/or HPV 18 infection. Nearly one-third (31.1%) had high grade, 10.3% had low grade, and 50.9% had no cervical disease. Nearly one-third (28.5%) had ever regularly smoked cigarettes, 70.7% had early onset of sexual intercourse, and 75% had ever used oral contraceptives. Conclusions: In this colposcopy clinic population with a range of clinical characteristics and established HPV cofactors, HPV DNA was undetectable in their serum. Our findings suggest that serum HPV DNA detection is not a cervical cancer screening tool.
UR - http://www.scopus.com/inward/record.url?scp=79952616581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952616581&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2011.01.002
DO - 10.1016/j.jcv.2011.01.002
M3 - Article
C2 - 21306941
AN - SCOPUS:79952616581
SN - 1386-6532
VL - 50
SP - 342
EP - 344
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
IS - 4
ER -